Evidence map›Paper›PMID 31067463›Full record

ArticleCell reports2019

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer.

Charles C Guo, Tadeusz Majewski, Li Zhang, Hui Yao, Jolanta Bondaruk, Yan Wang, Shizhen Zhang, Ziqiao Wang, June Goo Lee, Sangkyou Lee and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 148 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tadeusz MajewskiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhangDepartment of Environmental Health, University of Cincinnati, Cincinnati, OH, USA.
Hui YaoDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jolanta BondarukDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yan WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shizhen ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ziqiao WangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
June Goo LeeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangkyou LeeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David CogdellDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H Barton GrossmanDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jonathan James DupliseaDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James Edward FergusonDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
He HuangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vipulkumar DadhaniaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colin DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John N WeinsteinDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith BaggerlyDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David McConkeyJohns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University, Baltimore, MD, USA.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: bczernia@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USJohns Hopkins University · USUniversity of Cincinnati · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846
6 · The paper itself

Abstract

Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and 84 cases of conventional urothelial carcinoma (UC), with the TCGA cohort of 408 muscle-invasive bladder cancers serving as the reference. SARCs show a distinct mutational landscape, with enrichment of TP53, RB1, and PIK3CA mutations. They are related to the basal molecular subtype of conventional UCs and could be divided into epithelial-basal and more clinically aggressive mesenchymal subsets on the basis of TP63 and its target gene expression levels. Other analyses reveal that SARCs are driven by downregulation of homotypic adherence genes and dysregulation of the EMT network, and nearly half exhibit a heavily infiltrated immune phenotype. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer.

Indexed as

Disease ProgressionEpithelial-Mesenchymal TransitionAdultAgedAged, 80 and overFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMicroRNAsMiddle AgedMutagenesisMutationNeoplasm InvasivenessMicroRNAsbasal subtypebladder cancerchromatin remodelingepithelial-mesenchymal transformationgenomic expressionimmune phenotypemicroRNA expressionmolecular classificationsarcomatoid carcinomaurothelial carcinoma

Identifiers

PMID31067463
PMCPMC6546434
OpenAlexW2953226449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.